Clinical trial
A Phase 2 Study of Alisertib in Combination With Paclitaxel in Patients With Small Cell Lung Cancer
NCT07465757 is registered in ClinicalTrials.gov with Puma Biotechnology, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of Alisertib in Combination With Paclitaxel in Patients With Small Cell Lung Cancer
- Lead sponsor
- Puma Biotechnology, Inc.
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- September 17, 2026
- Completion date
- September 30, 2028
- Enrollment
- 50 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
small cell lung cancer ( sclc )